A controlled trial of value-based insurance design - The MHealthy: Focus on Diabetes (FOD) trial

Implementation Science

Volumn 4, Issue 1, 2009, Pages

  Spaulding, Alicen ^a,b   Fendrick, A Mark ^a,c   Herman, William H ^a,c   Stevenson, James G ^c   Smith, Dean G ^c   Chernew, Michael E ^d   Parsons, Dawn M ^c   Bruhnsen, Keith ^c   Rosen, Allison B ^a,c,e  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

^c UNIVERSITY OF MICHIGAN   (United States)

^d HARVARD MEDICAL SCHOOL   (United States)

^e VA ANN ARBOR HEALTHCARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 65349140015     PISSN: None     EISSN: 17485908     Source Type: Journal    
DOI: 10.1186/1748-5908-4-19     Document Type: Article

References (48)

1. National Diabetes Factsheet. http://apps.nccd.cdc.gov/ddtstrs/template/ ndfs-2005.pdf
2. The continuing epidemics of obesity and diabetes in the United States. Mokdad AH, Bowman BA, Ford ES, Vinicor F, Marks JS, Koplan JP. AH Mokdad BA Bowman ES Ford F Vinicor JS Marks JP Koplan, JAMA 2001 286 1195 1200 10.1001/jama.286.10.1195 11559264
3. Diabetes mellitus and macrovascular complications: An epidemiological perspective. RP Donahue TJ Orchard, Diabetes Care 1992 15 1141 1155 10.2337/diacare.15.9.1141 1396012
4. Factors accounting for the rise in health-care spending in the United States: the role of rising disease prevalence and treatment intensity. KE Thorpe, Public Health 2006 120 1002 1007 10.1016/j.puhe.2006.09.001 17030050 (Pubitemid 44567193)
5. Standards of medical care in diabetes 2008. American Diabetes Association, Diabetes Care 2008 31 S12 S54 10.2337/dc08-S012 18165335
6. Adherence to medication. L Osterberg T Blaschke, N Engl J Med 2005 353 487 497 10.1056/NEJMra050100 16079372 (Pubitemid 41127293)
7. A systematic review of adherence with medications for diabetes. JA Cramer, Diabetes Care 2004 27 1218 1224 10.2337/diacare.27.5.1218 15111553 (Pubitemid 38579798)
8. Hospital admissions resulting from preventable adverse drug reactions. PJ McDonnell MR Jacobs, Ann Pharmacother 2002 36 1331 1336 10.1345/aph.1A333 12196047
9. Decompensated heart failure: symptoms, patterns of onset, and contributing factors. GD Schiff S Fung T Speroff RA McNutt, Am J Med 2003 114 625 630 10.1016/S0002-9343(03)00132-3 12798449 (Pubitemid 36703230)
10. Practical approach to determining costs and frequency of adverse drug events in a health care network. BL Senst LE Achusim RP Genest LA Cosentino CC Ford JA Little SJ Raybon DW Bates, Am J Health Syst Pharm 2001 58 1126 1132 11449856 (Pubitemid 32552897)
11. Relationship between adherence to evidence-based pharmacotherapy and long-term mortality after acute myocardial infarction. JN Rasmussen A Chong DA Alter, JAMA 2007 297 177 186 10.1001/jama.297.2.177 17213401 (Pubitemid 46089734)
12. Labour productivity effects of prescribed medicines for chronically ill workers. JA Rizzo TA Abbott S Pashko, Health Econ 1996 5 249 265 10.1002/(SICI)1099-1050(199605)5:3<249::AID-HEC2033.0.CO;2-A 8817299 (Pubitemid 126482630)
13. Depression and diabetes: impact of depressive symptoms on adherence, function, and costs. PS Ciechanowski WJ Katon JE Russo, Arch Intern Med 2000 160 3278 3285 10.1001/archinte.160.21.3278 11088090
14. Economic costs of diabetes in the US in 2002. P Hogan T Dall P Nikolov American Diabetes Association, Diabetes Care 2003 26 917 932 10.2337/diacare.26.3.917 12610059 (Pubitemid 36929365)
15. Depression is a risk factor for noncompliance with medical treatment: meta-analysis of the effects of anxiety and depression on patient adherence. MR DiMatteo HS Lepper TW Croghan, Arch Intern Med 2000 160 2101 2107 10.1001/archinte.160.14.2101 10904452 (Pubitemid 30482715)
16. Interventions to enhance medication adherence. RB Haynes X Yao A Degani S Kripalani A Garg HP McDonald, Cochrane Database Syst Rev 2005 4 CD000011 16235271
17. Interventions to enhance medication adherence in chronic medical conditions: a systematic review. S Kripalani X Yao RB Haynes, Arch Intern Med 2007 167 540 550 10.1001/archinte.167.6.540 17389285 (Pubitemid 46513223)
18. Prescription drug cost sharing: associations with medication and medical utilization and spending and health. DP Goldman GF Joyce Y Zheng, JAMA 2007 298 61 69 10.1001/jama.298.1.61 17609491 (Pubitemid 47026771)
19. Suboptimal statin adherence and discontinuation in primary and secondary prevention populations. JJ Ellis SR Erickson JG Stevenson SJ Bernstein RA Stiles AM Fendrick, J Gen Intern Med 2004 19 638 645 15209602 10.1111/j.1525-1497. 2004.30516.x (Pubitemid 38803154)
20. Pharmacy benefits and the use of drugs by the chronically ill. DP Goldman GF Joyce JJ Escarce JE Pace MD Solomon M Laouri PB Landsman SM Teutsch, JAMA 2004 291 2344 2350 10.1001/jama.291.19.2344 15150206 (Pubitemid 38656301)
21. The impact of increasing patient prescription drug cost sharing on therapeutic classes of drugs received and on the health status of elderly HMO members. RE Johnson MJ Goodman MC Hornbrook MB Eldredge, Health Serv Res 1997 32 103 122 9108807 (Pubitemid 27172817)
22. Health insurance status, cost-related medication underuse, and outcomes among diabetes patients in three systems of care. JD Piette TH Wagner MB Potter D Schillinger, Med Care 2004 42 2 102 109 10.1097/01.mlr.0000108742.26446.17 14734946
23. Payment restrictions for prescription drugs under Medicaid. Effects on therapy, cost, and equity. SB Soumerai J Avorn D Ross-Degnan S Gortmaker, N Engl J Med 1987 317 550 556 3302713 (Pubitemid 17123270)
24. Adverse events associated with prescription drug cost-sharing among poor and elderly persons. R Tamblyn R Laprise JA Hanley M Abrahamowicz S Scott N Mayo J Hurley R Grad E Latimer R Perreault, JAMA 2001 285 4 421 429 10.1001/jama.285.4.421 11242426 (Pubitemid 32097260)
25. The health effects of restricting prescription medication use because of cost. M Heisler KM Langa EL Eby AM Fendrick MU Kabeto JD Piette, Med Care 2004 42 626 634 10.1097/01.mlr.0000129352.36733.cc 15213486
26. Impact of the cost of prescription drugs on clinical outcomes in indigent patients with heart disease. MD Schoen RJ DiDomenico SE Connor JE Dischler JL Bauman, Pharmacotherapy 2001 21 1455 1463 10.1592/phco.21.20.1455.34473 11765297 (Pubitemid 33117249)
27. Effects of Medicaid drug-payment limits on admission to hospitals and nursing homes. SB Soumerai D Ross-Degnan J Avorn T McLaughlin I Choodnovskiy, N Engl J Med 1991 325 1072 1077 1891009
28. A benefit-based copay for prescription drugs: patient contribution based on total benefits, not drug acquisition cost. AM Fendrick DG Smith ME Chernew SN Shah, Am J Manag Care 2001 7 861 867 11570020 (Pubitemid 32904146)
29. Value-Based Insurance Design. ME Chernew AB Rosen AM Fendrick, Health Affairs 2007 26 w195 w203 10.1377/hlthaff.26.2.w195 17264100
30. Grounding Coverage in Value: A Paradigm to Improve Quality and Contain Costs. AB Rosen, Med Care 2006 44 389 391 10.1097/01.mlr.0000216191.86056.a1 16641655
31. Linking cost-sharing to value: an unrivaled yet unrealized public health opportunity. RS Braithwaite AB Rosen, Annals of Internal Medicine 2007 146 602 605 17438319
32. From 'one size fits all' to tailored co-payments. S Hensley, Wall Street Journal. New York City 2004
33. The interaction of depression and diabetes: a review. PA Pirraglia S Gupta, Curr Diabetes Rev 2007 3 249 251 18220682 (Pubitemid 350111107)
34. Segmented regression analysis of interrupted time series studies in medication use research. AK Wagner SB Soumerai F Zhang D Ross-Degnan, J Clin Pharm Ther 2002 27 299 309 10.1046/j.1365-2710.2002.00430.x 12174032
35. MHealthy: Focus on Diabetes. http://www.hr.umich.edu/mhealthy/improve/ diabetes/index.html
36. MHealthy: Focus on Diabetes Questions and Answers. http://www.hr.umich. edu/mhealthy/improve/diabetes/diabetesqa.html
37. HEDIS & Quality Measurement. http://web.ncqa.org/tabid/59/Default. aspx
38. Impact of decreasing copayments on medication adherence within a disease management environment. ME Chernew MR Shah A Wegh SN Rosenberg IA Juster AB Rosen MC Sokol K Yu-Isenberg AM Fendrick, Health Affairs 2008 27 103 112 10.1377/hlthaff.27.1.103 18180484
39. Health care and medication costs and use among older adults with heart failure. KT Stroupe EY Teal M Weiner I Gradus-Pizlo DC Brater MD Murray, Am J Med 2004 116 443 450 10.1016/j.amjmed.2003.11.016 15047033 (Pubitemid 38388613)
40. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. RA Deyo DC Cherkin MA Ciol, J Clin Epidemiol 1992 45 613 619 10.1016/0895-4356(92)90133-8 1607900
41. An Iconoclastic View of Health Cost Containment. JP Newhouse, Health Affairs 1993 12 Supp 152 171 10.1377/hlthaff.12.suppl-1.152 (Pubitemid 23120202)
42. University of Michigan unveils innovative medication program for employees and dependents with diabetes. http://www.med.umich.edu/opm/newspage/ 2006/diabetes.htm
43. State lawmakers honor University for employee health programs. http://www.ur.umich.edu/0607/May21-07/19.shtml
44. Cost-effectiveness of full Medicare coverage of Angiotensin-Converting Enzyme Inhibitors for beneficiaries with diabetes. AB Rosen MB Hamel MC Weinstein DM Cutler AM Fendrick S Vijan, Ann Intern Med 2005 143 89 99 16027450 (Pubitemid 41001419)
45. A general method of compliance assessment using centralized pharmacy records: Description and validation. JF Steiner TD Koepsell SD Fihn TS Inui, Med Care 1988 26 814 823 10.1097/00005650-198808000-00007 3398608
46. Employer-sponsored health insurance in the United States-origins and implications. D Blumenthal, N Engl J Med 2006 355 82 88 10.1056/NEJMhpr060703 16823002
47. The Quality of Health Care Delivered to Adults in the United States. EA McGlynn SM Asch J Adams J Keesey J Hicks A DeCristofaro EA Kerr, N Engl J Med 2003 348 2635 2645 10.1056/NEJMsa022615 12826639 (Pubitemid 36741592)
48. Committee on Quality of Health Care in America, Institute of Medicine, Crossing the Quality Chasm: A New Health System for the 21st Century Washington, D.C.: National Academy Press 2001